
Former Seagen CEO Siegall pops up at new biotech
Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
Newsletters and Deep Dive digital magazine
Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.
New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.
IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.
Editor's Picks
Newsletters and Deep Dive
digital magazine